Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma

OBJECTIVE: Therapy-induced tumour microenvironment (TME) remodelling poses a major hurdle for cancer cure. As the majority of patients with hepatocellular carcinoma (HCC) exhibits primary or acquired resistance to antiprogrammed cell death (ligand)-1 (anti-PD-[L]1) therapies, we aimed to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Zhewen, Chan, Stephen Lam, Zhou, Jingying, Vong, Joaquim S.L., Kwong, Tsz Tung, Zeng, Xuezhen, Wu, Haoran, Cao, Jianquan, Tu, Yalin, Feng, Yu, Yang, Weiqin, Wong, Patrick Pak-Chun, Si-Tou, Willis Wai-Yiu, Liu, Xiaoyu, Wang, Jing, Tang, Wenshu, Liang, Zhixian, Lu, Jiahuan, Li, Ka Man, Low, Jie-Ting, Chan, Michael Wing-Yan, Leung, Howard H.W., Chan, Anthony W.H., To, Ka-Fai, Yip, Kevin Yuk-Lap, Lo, Yuk Ming Dennis, Sung, Joseph Jao-Yiu, Cheng, Alfred Sze-Lok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423534/
https://www.ncbi.nlm.nih.gov/pubmed/37019619
http://dx.doi.org/10.1136/gutjnl-2022-328364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423534/
https://www.ncbi.nlm.nih.gov/pubmed/37019619
http://dx.doi.org/10.1136/gutjnl-2022-328364

Ejemplares similares